EUR/USD, USD/JPY Watch: Pharming's Global Expansion Signals Steady FX Flows

Pharming Group's Q1 2026 results highlight cross-border pharmaceutical revenue dynamics with indirect forex implications. Total revenues declined 8% year-over-year to $72.4 million, driven by a 15% drop in RUCONEST revenue to $58.4 million amid planned inventory drawdowns and a strategic exit from non-US markets. However, Joenja revenue rose 34% to $14.1 million, reflecting strong US demand. The company's planned pediatric label expansion in the US and upcoming launches in Japan and Europe during 2026 suggest increasing international revenue flows that could generate incremental demand across EUR/USD and USD/JPY corridors. While this corporate earnings report has limited direct forex market impact, the broader theme of pharmaceutical multinationals rebalancing geographic revenue exposure—exiting certain non-US markets while expanding into Japan and Europe—reflects ongoing capital flow patterns that currency traders should note. The planned European and Japanese launches could modestly support EUR and JPY demand against the dollar in the medium term as repatriation flows materialize.